New cholesterol drug could improve cardiovascular health… But will insurers pay for it?

In clinical trials, a new drug class known as PCSK9 Inhibitors reduced bad cholesterol markedly and is expected to be approved by the FDA this summer. An expert in lipid management discusses some of the barriers to its use.

from Today's Healthcare News -- ScienceDaily http://ift.tt/1Bgd1eq